RECRUITING

Gait Analysis in Neurological Disease

Conditions

Parkinson's Disease Parkinsonian Disorders Atypical Parkinson Disease Progressive Supranuclear Palsy Multiple System Atrophy Corticobasal Degeneration Gait, Frontal Huntington Disease

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to investigate whether speed-dependent measures of gait can be identified in patients with neurological conditions that affect gait, particularly in subjects with parkinsonian disorders.

Official Title

Gait Pattern Analysis in Neurological Disease

Quick Facts

Study Start:2016-03-01

Study Completion:2025-06-20

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT02994719

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 85 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Age 18-85 (for both healthy and affected subjects). * Presence of at least 2 of the following: bradykinesia, rest tremor, rigidity, postural instability (UK PD Brain Bank Criteria) (Affected subjects only). * Montreal Cognitive Assessment will be employed to determine whether subjects will need the assent of a legally authorized representative. Subjects with MOCA ≤ 21 will be consented only with the assent of the subject and informed consent of the authorized legal representative (Affected subjects only). * These may include subjects who may have indeterminate parkinsonism, when it is not clear whether they have idiopathic Parkinson's Disease versus one of the Atypical Parkinsonisms, such as Vascular Parkinsonism, Multiple System Atrophy, Progressive Supranuclear Palsy, Normal Pressure Hydrocephalus or Corticobasal Degeneration (Affected subjects only). * Subjects with assistive devices will be eligible for the study and may use them during the study (Affected subjects only). * Absence of complaints regarding difficulty walking such as arthritic pain, fatigue during walking or slowness of walking (Healthy subjects only).	* Presence of alternative explanation for parkinsonism such as head trauma, drug-induced parkinsonism (affected subjects only). * Currently being treated for major medical illness requiring recent hospitalization (\<14 days) (for both healthy and affected subjects). * Currently participating in another clinical study with an intervention arm (for both healthy and affected subjects). * Inability to consent due to cognitive impairment and absence of legally authorized representative (for both healthy and affected subjects). * Subjects with any cardiac, pulmonary conditions (congestive heart failure requiring hospitalization within the past 90 days, recent myocardial infarction \< 90 days, supplemental oxygen-requiring subjects due to cardiac or pulmonary conditions) that limit their ability to safely participate in a walking trial (for both healthy and affected subjects).

Inclusion Criteria

Exclusion Criteria

* Age 18-85 (for both healthy and affected subjects).
* Presence of at least 2 of the following: bradykinesia, rest tremor, rigidity, postural instability (UK PD Brain Bank Criteria) (Affected subjects only).
* Montreal Cognitive Assessment will be employed to determine whether subjects will need the assent of a legally authorized representative. Subjects with MOCA ≤ 21 will be consented only with the assent of the subject and informed consent of the authorized legal representative (Affected subjects only).
* These may include subjects who may have indeterminate parkinsonism, when it is not clear whether they have idiopathic Parkinson's Disease versus one of the Atypical Parkinsonisms, such as Vascular Parkinsonism, Multiple System Atrophy, Progressive Supranuclear Palsy, Normal Pressure Hydrocephalus or Corticobasal Degeneration (Affected subjects only).
* Subjects with assistive devices will be eligible for the study and may use them during the study (Affected subjects only).
* Absence of complaints regarding difficulty walking such as arthritic pain, fatigue during walking or slowness of walking (Healthy subjects only).

* Presence of alternative explanation for parkinsonism such as head trauma, drug-induced parkinsonism (affected subjects only).
* Currently being treated for major medical illness requiring recent hospitalization (\<14 days) (for both healthy and affected subjects).
* Currently participating in another clinical study with an intervention arm (for both healthy and affected subjects).
* Inability to consent due to cognitive impairment and absence of legally authorized representative (for both healthy and affected subjects).
* Subjects with any cardiac, pulmonary conditions (congestive heart failure requiring hospitalization within the past 90 days, recent myocardial infarction \< 90 days, supplemental oxygen-requiring subjects due to cardiac or pulmonary conditions) that limit their ability to safely participate in a walking trial (for both healthy and affected subjects).

Contacts and Locations

Study Contact

Veronique Vanderhorst, MD PhD

CONTACT

617-667-0519

vvanderh@bidmc.harvard.edu

Study Locations (Sites)

Clinical Research Center BIDMC

Boston, Massachusetts, 02215

United States

Collaborators and Investigators

Sponsor: Beth Israel Deaconess Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2016-03-01

Study Completion Date2025-06-20

Study Record Updates

Study Start Date2016-03-01

Study Completion Date2025-06-20

Terms related to this study

Additional Relevant MeSH Terms

Parkinson's Disease
Parkinsonian Disorders
Atypical Parkinson Disease
Progressive Supranuclear Palsy
Multiple System Atrophy
Corticobasal Degeneration
Gait, Frontal
Huntington Disease